Fish oil enhances the antiproliferative effect of 1α,25- dihydroxyvitamin D3 on liver cancer cells

Anticancer Research

Volumn 29, Issue 9, 2009, Pages 3591-3596

  Chiang, Kun Chun ^a   Persons, Elly S ^b   Istfan, Nawfal W ^b   Holick, Michael F ^b   Chen, Tai C ^b  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

3 PUFAs; 1 25(OH)2D3; Fish oil; Hepatoma; HepG2; Proliferation; Vitamin D

Indexed keywords

CALCITRIOL; CORN OIL; FISH OIL;

ANTINEOPLASTIC ACTIVITY; CELL COUNT; CELL PROLIFERATION; CONFERENCE PAPER; CONTROLLED STUDY; DRUG POTENTIATION; HUMAN; HUMAN CELL; LIVER CANCER; PRIORITY JOURNAL;

CALCITRIOL; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SYNERGISM; FISH OILS; HUMANS; LIVER NEOPLASMS;

EID: 68549092570     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (31)

1. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108, 2005.
2. Ringe B, Pichlmayr R, Wittekind C and Tusch G: Surgical treatment of hepatocellular carcinoma: experience with liver resection and transplantation in 198 patients. World J Surg 15: 270-285, 1991.
3. Lai EC, Fan ST, Lo CM, Chu KM, Liu CL and Wong J: Hepatic resection for hepatocellular carcinoma. An audit of 343 patients. Ann Surg 221: 291-298, 1995.
4. Lee WC, Jeng LB and Chen MF: Hepatectomy for hepatitis B-, hepatitis C-, and dual hepatitis B- and C-related hepatocellular carcinoma in Taiwan. J Hepatobiliary Pancreat Surg 7: 265-269, 2000.
5. Lee PH, Lin WJ, Tsang YM, Hu RH, Sheu JC, Lai MY, Hsu HC, May W and Lee CS: Clinical management of recurrent hepatocellular carcinoma. Ann Surg 222: 670-676, 1995.
6. Kubo S, Kinoshita H, Hirohashi K, Tanaka H, Tsukamoto T, Hamba H, Shuto T, Yamamoto T, Ikebe T and Wakasa K: Patterns and risk factors for recurrence after liver resection for well-differentiated hepatocellular carcinoma: a special reference to multicenteric carcinogenesis after operation. Hepatogastroenterology 46: 3212-3215, 1999.
7. Poon RTP, Fan ST, Lo VM, Liu CL and Wong J: Intrahepatic recurrence after curative resection of hepatocellular carcinoma: long-term results of treatment and prognostic factors. Ann Surg 229: 216-222, 1999.
8. Lee WC, Jeng LB and Chen MF: Estimation of prognosis after hepatectomy for hepatocellular carcinoma. Br J Surg 89(3): 311-316, 2002. (Pubitemid 34227029)
9. 3. Proc Natl Acad Sci USA 76: 4990-4994, 1981. (Pubitemid 12225607)
10. 3 in hormone refractoy prostate cancer. Urol Oncol pp. 1195-1198, 1995.
11. 3 J Urol 159: 2035-2040, 1998. (Pubitemid 29190750)
12. Giovannucci E, Rimm EB, Colditz GA, Stampfer MJ, Ascherio A, Chute CC and Willett WC: A prospective study of dietary fat and rsik of prostate cancer, J Natl Cancer Inst 85: 1571-1579, 1993. (Pubitemid 23304685)
13. Leitzmann MF, Stampfer MJ, Michaud DS, Augustsson K, Colditz GC, Willett WC and Giovannucci EL: Dietary intake of n-3 and n-6 fatty acids and the risk of prostate cancer. Am J Clin Nutr 134: 204-216, 2004.
14. Brouwer IA, Katan MB and Zock PL: Dietary alpha-linolenic acid is associated with reduced risk of fatal coronary heart disease, but increased prostate cancer risk. A meta-analysis. J Nutr 134: 919-922, 2004.
15. Hardman WE: n-3 Fatty acids and cancer therapy. J Nutr 134(Suppl.): 3427s-3430s, 2004.
16. 2 for prostate cancer therapy. Clin Cancer Res 6: 901-908, 2000. (Pubitemid 30159347)
17. 3 are potentiated by epidermal growth factor and attenuated by insulin in cultured human keratinocytes. J Investig Dermatol 104: 113-117, 1995.
18. 3 and its analogues, EB1089 and CB1093, profoundly inhibit the in vitro proliferation of the human hepatoblastoma cell line HepG2. ANZ J Surg 71(7): 414-417, 2001. (Pubitemid 33755097)
19. Chen MF, Hwang TL, Jeng LB, Wang CS, Jan YY and Chen SC. Postoperative recurrence of hepatocellular carcinoma. Two hundred five consecutive patients who underwent hepatic resection in 15 years. Arch Surg 129: 738-742, 1994.
20. Yeh CN, Lee WC, Chen MF and Tsay PK: Predictors of long-term disease-free survival after resection of hepatocellular carcinoma: Two decades of experience at Chang Gung Memorial Hospital. Ann Surg Oncol 10(8): 916-921, 2003. (Pubitemid 40486857)
21. Colston KW, Berger U and Coombes RC: Possible role for vitamin D in controlling breast cancer proliferation. Lancet 1: 188-189, 1989. (Pubitemid 19038805)
22. 3. Cancer Res 47: 21-25, 1987.
23. 3 and malignant melanoma: the presence of receptors and inhibition of cell growth in culture. Endocrinology 108: 1083-1086, 1981.
24. 3. Cancer Lett 151: 97-102, 2000.
25. Finlay IG, Stewart GJ, Ahkter J and Morris DL: Hepatcellular carcinoma: Treatment and recurrence marker. A phase one study of the hepatic arterial administration of 1,25-dihydroxyvitamin D3 for liver cancers. J Gastroenterol Hepatol 16: 333-337, 2001.
26. Terry PD, Terry JB and Rohan TE: Long-chain (n-3) fatty acid intake and risk of cancers of the breast and the prostate: recent epidemiological studies, biological mechanisms, and directions for future research. J Nutr 134: 3412s-3420s, 2004.
27. Simopoulos AP: The omega-6/omega-3 fatty acid ratio, genetic variation, and cardiovascular disease. Asia Pac J Clin Nutr 17(Suppl 1): 131-134, 2008.
28. Hardman WE: (n-3) fatty acids and cancer therapy. J Nutr 134: 3427-3430S, 2004.
29. Larsson SC, Kumlin M, Ingelman-Sundberg M and Wolk A: Dietary long-chain n-3 fatty acids for the prevention of cancer: a review of potential mechanisms. Am J Clin Nutr 79: 935-945, 2004. (Pubitemid 41095944)
30. Krishnan AV, Moreno J, Nonn L, Malloy P, Swami S, Peng L, Peehl DM and Feldman D: Novel pathways that contribute to the anti-proliferative and chemopreventive activities of calcitriol in prostate cancer. J Ster Biochem Mol Biol 103: 694-702, 2007. (Pubitemid 46401340)
31. 3 analogs as therapeutic agents for prostate cancer. J Steroid Biochem Mol Biol 103(3-5): 717-720, 2007. (Pubitemid 46401314)